The cause for the discordant advia centaur xp ca19-9 results with the alternate method is unknown.
Siemens healthcare diagnostics is awaiting further information.
The instrument is performing within specifications.
The ifu states in the interpretation of results section: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings.
" do not use the advia centaur ca 19-9 assay as a screening test or for diagnosis.
Do not predict disease recurrence solely on levels of advia centaur ca 19-9.
Normal levels of advia centaur ca 19-9 do not always preclude the presence of disease.
Do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease.
Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals.
Additionally, elevated levels of ca 19-9 can be observed in patients with nonmalignant diseases.
Measurements of ca 19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.
Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.
Therefore, it is important to use assayspecific values to evaluate quality control results.
".
|
Siemens filed the initial mdr 1219913-2016-00139 on august 5, 2016.
On 08/17/2016 additional information: the customer provided the lot number used at the time of testing.
Lot 382, expiration date: 01/09/2017.
The patient was reported as healthy.
The alternate method result was used.
The pid is 854.
The customer does not have any patient sample remaining for further testing and investigation.
The customer is using a local blood collection tube and not from a registered manufacturer.
Since the patient sample was not repeated with the advia centaur xp ca 19-9 assay, it is impossible to determine if the elevated result was due to the assay or some kind of sampling error.
The cause for the discordant advia centaur xp ca19-9 results with the alternate methods is unknown.
The instrument is performing within specifications.
No further evaluation of the device is required.
|